Silo Pharma enters exclusive global license with Columbia University for PTSD candidate SPC-15

Silo Pharma, Inc.

License covers patents and technical info for SPC-15, an intranasal treatment for stress-induced affective disorders and PTSD.
Agreement includes initial and annual fees from low to mid five figures, milestone payments, and royalties on net revenues.
Silo submitted a pre-IND briefing package to FDA and plans 505(b)(2) pathway to shorten clinical timelines and reduce costs.
Term runs per country/product until later of patent expiry, 20 years after first commercial sale, or end of market exclusivity.
CEO Eric Weisblum states the license is a critical step that could increase shareholder value subject to FDA approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.